Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analysts’ consensus rating is “Hold” for Verrica Pharmaceuticals, based on one sell, one hold, and two buy recommendations. The average 12-month price target is $14.50, well above the stock’s reported price of $4.99.
• Institutional investors and hedge funds own 42.45% of the company, with several funds adding new or larger positions during recent quarters.
• Verrica is a clinical-stage biopharmaceutical company developing topical dermatology treatments, including lead candidate VP-102 for molluscum contagiosum and common warts, alongside next-generation candidate VP-103.

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) has been given an average recommendation of "Hold" by the four research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $14.50.

Several analysts recently commented on the company. HC Wainwright began coverage on Verrica Pharmaceuticals in a research report on Tuesday, May 26th. They set a "buy" rating and a $12.00 price target for the company. Zacks Research upgraded Verrica Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Monday, May 11th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, July 15th. Finally, Wall Street Zen lowered shares of Verrica Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Armistice Capital LLC grew its stake in Verrica Pharmaceuticals by 75.1% during the 4th quarter. Armistice Capital LLC now owns 1,118,925 shares of the company's stock valued at $9,298,000 after acquiring an additional 479,732 shares in the last quarter. Affinity Asset Advisors LLC purchased a new position in Verrica Pharmaceuticals in the 4th quarter worth approximately $5,878,000. Velan Capital Investment Management LP acquired a new position in shares of Verrica Pharmaceuticals during the 4th quarter worth approximately $3,919,000. Boothbay Fund Management LLC acquired a new position in shares of Verrica Pharmaceuticals during the 3rd quarter worth approximately $1,210,000. Finally, Kalehua Capital Management LLC purchased a new stake in shares of Verrica Pharmaceuticals in the fourth quarter valued at approximately $1,959,000. 42.45% of the stock is currently owned by institutional investors and hedge funds.

Verrica Pharmaceuticals Price Performance

NASDAQ:VRCA opened at $4.99 on Thursday. The stock has a 50 day moving average of $5.64 and a two-hundred day moving average of $5.90. Verrica Pharmaceuticals has a 12 month low of $3.28 and a 12 month high of $9.82. The firm has a market cap of $85.73 million, a P/E ratio of -2.99 and a beta of 1.49. The company has a current ratio of 1.45, a quick ratio of 1.33 and a debt-to-equity ratio of 0.18.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica's approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source